WHO EXPERT COMMITTEE
ON BIOLOGICAL
STANDARDIZATION

Fifty-sixth Report

World Health Organization

Geneva 2007
Contents

Introduction
  Opening remarks by Secretary of the Expert Committee 2

General
  Developments in biological standardization 2
  WHO programmatic issues 2
  Vaccines and biological therapeutic products 4
  Maintenance of capacity for production of MCR-5 human diploid fibroblast cells 6
  Blood products and related in vitro diagnostic devices (IVDs) 8
  Advancement of technical expertise of regulatory authorities in the area of blood products and IVDs 10
  Quality, safety and efficacy of animal plasma-derived antisera 10
  Global needs in standardization of products derived by biotechnology 12
  International Non-proprietary Names for gene therapy products 13
  Reports from the WHO International Laboratories and WHO Collaborating Centres 14
  Feedback from users of WHO biological standardization products 19

International guidelines, recommendations and other matters related to the manufacture and quality control of biologicals 20
  Guidelines for assuring the quality and nonclinical safety evaluation of DNA vaccines 20
  Recommendations for rabies vaccines 21
  Guidelines to assure the quality, safety and efficacy of live attenuated rotavirus vaccines (oral) 22
  WHO Biosafety guidelines for the production and quality control of human influenza pandemic vaccine strains 23
  Recommendations for whole cell pertussis vaccines 24
  Recommendations for the production, control and regulation of human plasma for fractionation 25
  WHO guidelines on transmissible spongiform encephalopathies in relation to biological and pharmaceutical products 25
  Guidelines to assure the quality, safety and efficacy of human cells and tissues for transplantation 27
  Guidelines for good manufacturing practice for biological products 29
  Guidelines for good manufacturing practice for blood establishments 30
  Stability of vaccines 31
  Flavivirus vaccines — regulatory expectations 32
  Guidelines for acellular pertussis vaccines 33
  Recommendations for bacille Calmette-Guérin vaccines 34

International reference materials 35
  Proposals for discontinuation of reference preparations 35
Antigens and related substances

Yellow fever vaccine — minimum specifications in International Units per 0.5 ml dose 36
Smallpox vaccine — stability studies 37
Poliovirus, Sabin type 3 — neurovirulence test reference 38
Haemophilus influenzae type b capsular polysaccharide 39

Antisera

Dengue virus antibody, human serum 40
Japanese encephalitis virus, human serum 41
Anti-human platelet antigen-1a 42

Blood products and related substances

World Health Organization/International Society of Thrombosis and Haemostasis Liaison Committee report 43
Anti-A and anti-B blood grouping reagents 44
Prothrombin mutation 46
Vitamin B12 and folate in human serum 47
Blood coagulation factor V (plasma) human 47
Blood coagulation factor XI (plasma) human 48
Thromboplastin, rabbit, plain 49

Cytokines, growth factors and endocrinological substances

Vascular endothelial growth factor 49
Keratinocyte growth factor 50
Measurement of relative potencies of thermal degradation samples of the WHO international standard of interferon alpha 2b 51

Diagnostic reagents

Reference materials for in vitro diagnostic devices 53
HIV-1 RNA nucleic acid amplification test 53
Anti-HIV tests 54

Annex 1
Guidelines for assuring the quality and non-clinical safety evaluation of DNA vaccines 57

Annex 2
Recommendations for inactivated rabies vaccine for human use produced in cell substrates and embryonated eggs 83

Annex 3
Guidelines to assure the quality, safety and efficacy of live attenuated rotavirus vaccines (oral) 133

Annex 4
Recommendations for the production, control and regulation of human plasma for fractionation 189
Annex 5
WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines 265

Annex 6
Recommendations for whole cell pertussis vaccine 301

Annex 7
Biological Substances: international standards and reference reagents 335

Annex 8
Recommendations, guidelines and other documents for biological substances used in medicine 337